4.6 Review

Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review

Journal

VALUE IN HEALTH
Volume 19, Issue 2, Pages 255-266

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jval.2015.11.003

Keywords

infectious diseases; literature review; pediatric; utilities; vaccine-preventable.

Funding

  1. Sanofi Pasteur MSD

Ask authors/readers for more resources

Background: Cost-effectiveness analysis of pediatric vaccines for infectious diseases often requires quality-of-life (utility) weights. Objective: To investigate how utility weights have been elicited and used in this context. Methods: A systematic review was conducted of studies published between January 1990 and July 2013 that elicited or used utility weights in cost-effectiveness analyses of vaccines for pediatric populations. The review focused on vaccines for 17 infectious diseases and is presented following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology. Results: A total of 6410 titles and abstracts and 225 full-text articles were reviewed. Of those selected for inclusion (n = 101), 15 articles described the elicitation of utility weights and 86 described economic modeling studies using utilities. Various methods were used to generate utilities, including time trade-off, contingent valuation, and willingness to pay, as well as a preference-based measure with associated value sets, such as the EuroQol five-dimensional questionnaire or the Health Utilities Index. In modeling studies, the source of utilities used was often unclear, poorly reported, or based on weak underlying evidence. We found no articles that reported on the elicitation or use of utilities in diphtheria, polio, or tetanus. Conclusions: The scarcity of appropriate utility weights for vaccine preventable infectious diseases in children and a lack of standardization in their use in economic assessments limit the ability to accurately assess the benefits associated with interventions to prevent infectious diseases. This is an issue that should be of concern to those making decisions regarding the prevention and treatment of infectious childhood illnesses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

HEADROOM APPROACH TO DEVICE DEVELOPMENT: CURRENT AND FUTURE DIRECTIONS

Alan Girling, Richard Lilford, Amanda Cole, Terry Young

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2015)

Article Economics

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

Luis Hernandez, Shien Guo, Hector Toro-Diaz, Stuart Carroll, Syed Feisal Syed Farooq

JOURNAL OF MEDICAL ECONOMICS (2017)

Review Economics

A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?

Emma Cowles, Grace Marsden, Amanda Cole, Nancy Devlin

APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)

Article Oncology

Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis

Seye Abogunrin, Gian Luca Di Tanna, Sam Keeping, Stuart Carroll, Ike Iheanacho

BMC CANCER (2014)

Article Health Care Sciences & Services

Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the zoster quality of life (ZQOL) study

Mick Serpell, Adam Gater, Stuart Carroll, Linda Abetz-Webb, Azharul Mannan, Robert Johnson

HEALTH AND QUALITY OF LIFE OUTCOMES (2014)

Review Immunology

The association of human papillomavirus vaccination with sexual behaviours and human papillomavirus knowledge: a systematic review

Victoria A. H. Coles, Ajay S. Patel, Felicity L. Allen, Sam T. Keeping, Stuart M. Carroll

INTERNATIONAL JOURNAL OF STD & AIDS (2015)

Article Public, Environmental & Occupational Health

Quantifying the direct secondary health care cost of seasonal influenza in England

Joe W. E. Moss, Craig Davidson, Richard Mattock, Ilana Gibbons, Stuart Mealing, Stuart Carroll

BMC PUBLIC HEALTH (2020)

Article Environmental Sciences

Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare

Denis Horgan, Bettina Borisch, Ivana Cattaneo, Mark Caulfield, Arturo Chiti, Christine Chomienne, Amanda Cole, Karen Facey, Allan Hackshaw, Minna Hendolin, Nadia Georges, Dipak Kalra, Birute Tumiene, Martina von Meyenn

Summary: The potential of real-world data to improve healthcare research, delivery of care, and patient outcomes is recognized, but it requires frameworks for public trust and data access, cross-border governance, alignment of evidence frameworks, and addressing challenges in data curation.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)

Article Immunology

Estimates of the Global Burden of COVID-19 and the Value of Broad and Equitable Access to COVID-19 Vaccines

Eleanor Bell, Simon Brassel, Edward Oliver, Hannah Schirrmacher, Sofie Arnetorp, Katja Berg, Duncan Darroch-Thompson, Paula Pohja-Hutchison, Bruce Mungall, Stuart Carroll, Maarten Postma, Lotte Steuten

Summary: This research provides an overview of the global burden of COVID-19 and estimates the value of access to COVID-19 vaccines. Low-income countries allocate more resources to COVID-19 compared to high-income countries, and all countries experience lower than predicted economic growth. If all eligible countries achieve broader and more equitable access, more deaths could be averted and substantial healthcare savings could be achieved. The cost to high-income countries of not vaccinating all countries far exceeds the cost of global vaccine manufacturing and distribution.

VACCINES (2022)

Article Economics

Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales

Richard Mattock, Ilana Gibbons, Joe Moss, Stuart Mealing, Nathalie Largeron, Stuart Carroll, Fabian P. Alvarez

Summary: The cost-effectiveness analysis showed that in the 65+ population in England and Wales, using HD TIV instead of aTIV has better clinical benefits and economic outcomes. HD TIV can reduce the number of influenza cases, deaths, hospitalizations, and GP appointments.

JOURNAL OF MEDICAL ECONOMICS (2021)

Review Microbiology

Burden of selected infectious diseases covered by UK childhood vaccinations: systematic literature review

James Clark-Wright, Pollyanna Hudson, Conor McCloskey, Stuart Carroll

FUTURE MICROBIOLOGY (2020)

Article Economics

Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment

Amanda Cole, Koonal Shah, Brendan Mulhern, Yan Feng, Nancy Devlin

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2018)

No Data Available